{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:51:46Z","timestamp":1791269506203,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":104,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This Perspective outlines the challenges addressed at the first Annual Parkinson\u2019s Disease (PD) Prevention Think Tank, held on November 20\u201321, 2025 in Gainesville, Florida at the Fixel Institute. Over the course of two days, attendees from a wide variety of disciplines, including movement disorders neurology, environmental sciences, agriculture, public policy, public health, patient advocate groups, and more, discussed the current state of primary prevention research in PD, examined the lessons learned from prevention research in other disorders, and identified necessary regulatory and policy actions for moving toward primary prevention of PD. Eight key components of primary prevention are identified (8\u2009C\u2019s): accurately Count incidence and prevalence, Conduct longitudinal cohort studies, induce policy Change, Counsel on individual behavior change, Communicate clearly with the general public and with key stakeholders, form multi-centric Coalitions across neurodegenerative disorders, apply Cross-disciplinary approaches, and provide sustained financial Commitment to support ongoing prevention and mitigation efforts. These proceedings serve as an initial call-to-action for at-risk individuals, the clinicians who care for them, and for policymakers.<\/jats:p>","DOI":"10.1038\/s41531-026-01437-1","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:26:01Z","timestamp":1782188761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Primary prevention of Parkinson\u2019s disease: proceedings, the 8C\u2019s and a position statement from the Parkinson\u2019s disease prevention think tank"],"prefix":"10.1038","volume":"12","author":[{"given":"Sneha","family":"Mantri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhoda","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Blake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Borum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briana","family":"de Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Ray","family":"Dorsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruogu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Daniel","family":"Fenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue J.","family":"Goldie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel M.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Gonzalez-Latapi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego L.","family":"Guarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Kryzyzanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Lessard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andi","family":"Lipstein Fristedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejas R.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Norcini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Purks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Schiehser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Schwarzschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Temkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Bryan","family":"Unruh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Vulpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Wallock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cordelia","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison W.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Okun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"1437_CR1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"ER Dorsey","year":"2018","unstructured":"Dorsey, E. R. et al. Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 17, 939\u2013953 (2018).","journal-title":"Lancet Neurol."},{"key":"1437_CR2","doi-asserted-by":"publisher","first-page":"e080952","DOI":"10.1136\/bmj-2024-080952","volume":"388","author":"D Su","year":"2025","unstructured":"Su, D. et al. Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ 388, e080952 (2025).","journal-title":"BMJ"},{"key":"1437_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41531-023-00523-y","volume":"9","author":"C Pearson","year":"2023","unstructured":"Pearson, C. et al. Care access and utilization among medicare beneficiaries living with Parkinson\u2019s disease. NPJ Parkinsons Dis. 9, 108 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"1437_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-022-00410-y","volume":"8","author":"AW Willis","year":"2022","unstructured":"Willis, A. W. et al. Incidence of Parkinson disease in North America. npj Parkinsons Dis. 8, 1\u20137 (2022).","journal-title":"npj Parkinsons Dis."},{"key":"1437_CR5","first-page":"405","volume":"28","author":"H Albarmawi","year":"2022","unstructured":"Albarmawi, H. et al. The economic burden of Parkinson disease among Medicare beneficiaries. J. Manag Care Spec. Pharm. 28, 405\u2013414 (2022).","journal-title":"J. Manag Care Spec. Pharm."},{"key":"1437_CR6","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1002\/mds.29995","volume":"39","author":"A Wijers","year":"2024","unstructured":"Wijers, A., Ravi, A., Evers, S. M. A. A., Tissingh, G. & van Mastrigt, G. A. P. G. Systematic Review of the Cost of Illness of Parkinson\u2019s Disease from a Societal Perspective. Mov. Disord. 39, 1938\u20131951 (2024).","journal-title":"Mov. Disord."},{"key":"1437_CR7","first-page":"1","volume":"6","author":"W Yang","year":"2020","unstructured":"Yang, W. et al. Current and projected future economic burden of Parkinson\u2019s disease in the U. S. npj Parkinsons Dis. 6, 1\u20139 (2020).","journal-title":"S. npj Parkinsons Dis."},{"key":"1437_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-019-0074-8","volume":"5","author":"S Mantri","year":"2019","unstructured":"Mantri, S., Fullard, M. E., Beck, J. & Willis, A. W. State-level prevalence, health service use, and spending vary widely among Medicare beneficiaries with Parkinson disease. npj Parkinsons Dis. 5, 1 (2019).","journal-title":"npj Parkinsons Dis."},{"key":"1437_CR9","doi-asserted-by":"publisher","unstructured":"McKenzie, J. F. & Seabert, D. M. Prevention: Primary, Secondary, and Tertiary. in Encyclopedia of Epidemiology 839\u2013840 (SAGE Publications, Inc., 2008). https:\/\/doi.org\/10.4135\/9781412953948.","DOI":"10.4135\/9781412953948"},{"key":"1437_CR10","doi-asserted-by":"publisher","first-page":"S381","DOI":"10.3233\/JPD-240164","volume":"14","author":"GF Crotty","year":"2024","unstructured":"Crotty, G. F., Ayer, S. J. & Schwarzschild, M. A. Designing the first trials for Parkinson\u2019s prevention. J. Parkinsons Dis. 14, S381\u2013S393 (2024).","journal-title":"J. Parkinsons Dis."},{"key":"1437_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41531-021-00162-1","volume":"7","author":"CM Tanner","year":"2021","unstructured":"Tanner, C. M. et al. The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative Parkinsonism. npj Parkinsons Dis. 7, 16 (2021).","journal-title":"npj Parkinsons Dis."},{"key":"1437_CR12","first-page":"100369","volume":"13","author":"SG Young","year":"2025","unstructured":"Young, S. G., Elwell, K. & Watts, C. R. Regional changes in the prevalence of Parkinson\u2019s disease over a ten-year period in the state of Texas. Clin. Park Relat. Disord. 13, 100369 (2025).","journal-title":"Clin. Park Relat. Disord."},{"key":"1437_CR13","doi-asserted-by":"publisher","first-page":"107288","DOI":"10.1016\/j.parkreldis.2025.107288","volume":"132","author":"B Krzyzanowski","year":"2025","unstructured":"Krzyzanowski, B., Beyene, K. M., Nielsen, S. S., Killion, J. A. & Racette, B. A. Cropland associated with risk of Parkinson\u2019s disease in the northern Great Plains. Parkinsonism Relat. Disord. 132, 107288 (2025).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1437_CR14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3233\/JPD-191793","volume":"10","author":"MR Silver","year":"2020","unstructured":"Silver, M. R., Racette, B. A., Dube, U., Faust, I. M. & Searles Nielsen, S. Well Water and Parkinson\u2019s Disease in Medicare Beneficiaries: A Nationwide Case-Control Study. J. Parkinsons Dis. 10, 693\u2013705 (2020).","journal-title":"J. Parkinsons Dis."},{"key":"1437_CR15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.puhe.2024.10.035","volume":"237","author":"Y Xu","year":"2024","unstructured":"Xu, Y., Su, Y., Cai, S., Yao, Y. & Chen, X. Environmental and occupational exposure to organochlorine pesticides associated with Parkinson\u2019s disease risk: a systematic review and meta-analysis based on epidemiological evidence. Public Health 237, 374\u2013386 (2024).","journal-title":"Public Health"},{"key":"1437_CR16","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.2147\/NDT.S479757","volume":"20","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. Mechanisms of neurotoxicity of organophosphate pesticides and their relation to neurological disorders. Neuropsychiatr. Dis. Treat. 20, 2237\u20132254 (2024).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"1437_CR17","doi-asserted-by":"publisher","first-page":"e214174","DOI":"10.1212\/WNL.0000000000214174","volume":"105","author":"B Krzyzanowski","year":"2025","unstructured":"Krzyzanowski, B., Beyene, K. M., Turner, J. R. & Racette, B. A. Ambient trichloroethylene exposure and parkinson disease risk in medicare beneficiaries. Neurology 105, e214174 (2025).","journal-title":"Neurology"},{"key":"1437_CR18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/EDE.0000000000000987","volume":"30","author":"N Pearce","year":"2019","unstructured":"Pearce, N., Vandenbroucke, J. & Lawlor, D. A. Causal inference in environmental epidemiology: old and new. Epidemiology 30, 311\u2013316 (2019).","journal-title":"Epidemiology"},{"key":"1437_CR19","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s10654-020-00703-7","volume":"36","author":"M Shimonovich","year":"2021","unstructured":"Shimonovich, M., Pearce, A., Thomson, H., Keyes, K. & Katikireddi, S. V. Assessing causality in epidemiology: revisiting Bradford Hill to incorporate developments in causal thinking. Eur. J. Epidemiol. 36, 873\u2013887 (2021).","journal-title":"Eur. J. Epidemiol."},{"key":"1437_CR20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.envint.2014.11.002","volume":"75","author":"M Furlong","year":"2015","unstructured":"Furlong, M. et al. Protective glove use and hygiene habits modify the associations of specific pesticides with Parkinson\u2019s disease. Environ. Int 75, 144\u2013150 (2015).","journal-title":"Environ. Int"},{"key":"1437_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.parkreldis.2013.09.023","volume":"20","author":"F Kamel","year":"2014","unstructured":"Kamel, F. et al. Dietary fat intake, pesticide use, and Parkinson\u2019s disease. Parkinsonism Relat. Disord. 20, 82\u201387 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1437_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/jox15060187","volume":"15","author":"TR Fagundes","year":"2025","unstructured":"Fagundes, T. R., Coradi, C., Vacario, B. G. L., de Morais Valentim, J. M. B. & Panis, C. Global evidence on monitoring human pesticide exposure. J. Xenobiot. 15, 187 (2025).","journal-title":"J. Xenobiot."},{"key":"1437_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemosphere.2025.144348","volume":"377","author":"L Amaral","year":"2025","unstructured":"Amaral, L. et al. The neurotoxicity of pesticides: Implications for Parkinson\u2019s disease. Chemosphere 377, 144348 (2025).","journal-title":"Chemosphere"},{"key":"1437_CR24","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/labinvest.2015.161","volume":"96","author":"X-F Zhang","year":"2016","unstructured":"Zhang, X.-F., Thompson, M. & Xu, Y.-H. Multifactorial theory applied to the neurotoxicity of paraquat and paraquat-induced mechanisms of developing Parkinson\u2019s disease. Lab Invest 96, 496\u2013507 (2016).","journal-title":"Lab Invest"},{"key":"1437_CR25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.neuroscience.2025.08.060","volume":"585","author":"H Singh","year":"2025","unstructured":"Singh, H., Kumari, S. & Taliyan, R. Epigenetic mechanisms linking environmental exposure to Parkinson\u2019s disease: A comprehensive review. Neuroscience 585, 367\u2013380 (2025).","journal-title":"Neuroscience"},{"key":"1437_CR26","doi-asserted-by":"publisher","first-page":"11848","DOI":"10.1007\/s12035-025-05000-6","volume":"62","author":"F Bosak","year":"2025","unstructured":"Bosak, F. et al. Evaluation of the protective effects of noscapine on paraquat-induced Parkinson\u2019s disease in rats. Mol. Neurobiol. 62, 11848\u201311876 (2025).","journal-title":"Mol. Neurobiol."},{"key":"1437_CR27","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.expneurol.2010.02.007","volume":"223","author":"A Kachroo","year":"2010","unstructured":"Kachroo, A., Irizarry, M. C. & Schwarzschild, M. A. Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Exp. Neurol. 223, 657\u2013661 (2010).","journal-title":"Exp. Neurol."},{"key":"1437_CR28","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.ibneur.2026.02.008","volume":"20","author":"S Shalikar","year":"2026","unstructured":"Shalikar, S., Mashayekhpour, M. A., Ebrahimi Vosta-Kalaee, S., Abouhosseini Tabari, M. & Hajizadeh Moghaddam, A. Frankincense improves motor symptoms and attenuates the progression of Paraquat (PQ)-induced Parkinson\u2019s disease in mice by attenuating oxidative stress, inflammation, and apoptotic cell death and improving nerve growth factor gene expression. IBRO Neurosci. Rep. 20, 276\u2013285 (2026).","journal-title":"IBRO Neurosci. Rep."},{"key":"1437_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13024-025-00915-z","volume":"21","author":"KMM Hasan","year":"2025","unstructured":"Hasan, K. M. M. et al. The pesticide chlorpyrifos increases the risk of Parkinson\u2019s disease. Mol. Neurodegener. 21, 3 (2025).","journal-title":"Mol. Neurodegener."},{"key":"1437_CR30","doi-asserted-by":"publisher","DOI":"10.14573\/altex.2412051","author":"A Zwartsen","year":"2025","unstructured":"Zwartsen, A. et al. Towards NAM-based risk assessment for developmental neurotoxic effects, illustrated with chlorpyrifos. ALTEX https:\/\/doi.org\/10.14573\/altex.2412051 (2025).","journal-title":"ALTEX"},{"key":"1437_CR31","doi-asserted-by":"publisher","first-page":"15336","DOI":"10.1007\/s12035-025-05172-1","volume":"62","author":"R Liu","year":"2025","unstructured":"Liu, R., Zhang, F., Lou, J. & Song, F. Trichloroethylene exposure and Parkinson\u2019s disease: environmental risk, metabolic pathways, and mechanistic insights. Mol. Neurobiol. 62, 15336\u201315348 (2025).","journal-title":"Mol. Neurobiol."},{"key":"1437_CR32","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1039\/C9EM00578A","volume":"22","author":"BR De Miranda","year":"2020","unstructured":"De Miranda, B. R. & Greenamyre, J. T. Trichloroethylene, a ubiquitous environmental contaminant in the risk for Parkinson\u2019s disease. Environ. Sci. Process Impacts 22, 543\u2013554 (2020).","journal-title":"Environ. Sci. Process Impacts"},{"key":"1437_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ccell.2005.11.006","volume":"18","author":"RL Corelli","year":"2006","unstructured":"Corelli, R. L. & Hudmon, K. S. Pharmacologic interventions for smoking cessation. Crit. Care Nurs. Clin. North Am. 18, 39\u201351, xii (2006).","journal-title":"Crit. Care Nurs. Clin. North Am."},{"key":"1437_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03087-z","volume":"21","author":"T Nian","year":"2023","unstructured":"Nian, T. et al. Non-pharmacological interventions for smoking cessation: analysis of systematic reviews and meta-analyses. BMC Med 21, 378 (2023).","journal-title":"BMC Med"},{"key":"1437_CR35","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1056\/NEJMp1004152","volume":"362","author":"L Deyton","year":"2010","unstructured":"Deyton, L., Sharfstein, J. & Hamburg, M. Tobacco Product Regulation \u2014 A Public Health Approach. N. Engl. J. Med. 362, 1753\u20131756 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1437_CR36","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/ntr\/ntaa156","volume":"23","author":"JT Chang","year":"2021","unstructured":"Chang, J. T., Anic, G. M., Rostron, B. L., Tanwar, M. & Chang, C. M. Cigarette Smoking Reduction and Health Risks: A Systematic Review and Meta-analysis. Nicotine Tob. Res 23, 635\u2013642 (2021).","journal-title":"Nicotine Tob. Res"},{"key":"1437_CR37","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10823-014-9233-x","volume":"29","author":"S Pan","year":"2014","unstructured":"Pan, S., Stutzbach, J., Reichwein, S., Lee, B. K. & Dahodwala, N. Knowledge and attitudes about Parkinson\u2019s disease among a diverse group of older adults. J. Cross Cult. Gerontol. 29, 339\u2013352 (2014).","journal-title":"J. Cross Cult. Gerontol."},{"key":"1437_CR38","doi-asserted-by":"publisher","first-page":"e1011251","DOI":"10.1371\/journal.pcbi.1011251","volume":"19","author":"BG Borowiec","year":"2023","unstructured":"Borowiec, B. G. Ten simple rules for scientists engaging in science communication. PLoS Comput Biol. 19, e1011251 (2023).","journal-title":"PLoS Comput Biol."},{"key":"1437_CR39","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000200110","volume":"10","author":"N Pankratz","year":"2024","unstructured":"Pankratz, N., Cole, B. R., Beutel, K. M., Liao, K. P. & Ashe, J. Parkinson disease genetics extended to African and hispanic ancestries in the VA Million Veteran Program. Neurol. Genet 10, e200110 (2024).","journal-title":"Neurol. Genet"},{"key":"1437_CR40","volume":"12","author":"S O\u2019Shea","year":"2025","unstructured":"O\u2019Shea, S. et al. Obesity and the development of Parkinson\u2019s disease within the Framingham Heart Study cohort. Clin. Park Relat. Disord. 12, 100291 (2025).","journal-title":"Clin. Park Relat. Disord."},{"key":"1437_CR41","doi-asserted-by":"publisher","first-page":"106986","DOI":"10.1016\/j.parkreldis.2024.106986","volume":"126","author":"A-GP Dennis","year":"2024","unstructured":"Dennis, A.-G. P. & Strafella, A. P. The role of AI and machine learning in the diagnosis of Parkinson\u2019s disease and atypical Parkinsonisms. Parkinsonism Relat. Disord. 126, 106986 (2024).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1437_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102410","volume":"99","author":"A Reddy","year":"2024","unstructured":"Reddy, A. et al. Artificial intelligence in Parkinson\u2019s disease: Early detection and diagnostic advancements. Ageing Res Rev. 99, 102410 (2024).","journal-title":"Ageing Res Rev."},{"key":"1437_CR43","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41531-025-01082-0","volume":"11","author":"DL Guar\u00edn","year":"2025","unstructured":"Guar\u00edn, D. L. et al. Video analysis reveals early signs of Bradykinesia in REM sleep behavior disorder and Parkinson\u2019s disease. NPJ Parkinsons Dis. 11, 222 (2025).","journal-title":"NPJ Parkinsons Dis."},{"key":"1437_CR44","doi-asserted-by":"publisher","first-page":"107104","DOI":"10.1016\/j.parkreldis.2024.107104","volume":"127","author":"DL Guar\u00edn","year":"2024","unstructured":"Guar\u00edn, D. L., Wong, J. K., McFarland, N. R., Ramirez-Zamora, A. & Vaillancourt, D. E. What the trained eye cannot see: Quantitative kinematics and machine learning detect movement deficits in early-stage Parkinson\u2019s disease from videos. Parkinsonism Relat. Disord. 127, 107104 (2024).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1437_CR45","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.3233\/JPD-202453","volume":"11","author":"MA Little","year":"2021","unstructured":"Little, M. A. Smartphones for remote symptom monitoring of Parkinson\u2019s Disease. J. Parkinsons Dis. 11, S49\u2013S53 (2021).","journal-title":"J. Parkinsons Dis."},{"key":"1437_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102651","volume":"104","author":"I Karimi-Sani","year":"2025","unstructured":"Karimi-Sani, I. et al. Drug repositioning for Parkinson\u2019s disease: an emphasis on artificial intelligence approaches. Ageing Res Rev. 104, 102651 (2025).","journal-title":"Ageing Res Rev."},{"key":"1437_CR47","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/med.21764","volume":"41","author":"S Vatansever","year":"2021","unstructured":"Vatansever, S. et al. Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: state-of-the-arts and future directions. Med Res Rev. 41, 1427\u20131473 (2021).","journal-title":"Med Res Rev."},{"key":"1437_CR48","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1177\/1090198111418634","volume":"39","author":"SD Golden","year":"2012","unstructured":"Golden, S. D. & Earp, J. A. L. Social ecological approaches to individuals and their contexts: twenty years of health education & behavior health promotion interventions. Health Educ. Behav. 39, 364\u2013372 (2012).","journal-title":"Health Educ. Behav."},{"key":"1437_CR49","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1515\/revneuro-2012-0087","volume":"24","author":"R Grazina","year":"2013","unstructured":"Grazina, R. & Massano, J. Physical exercise and Parkinson\u2019s disease: influence on symptoms, disease course and prevention. Rev. Neurosci. 24, 139\u2013152 (2013).","journal-title":"Rev. Neurosci."},{"key":"1437_CR50","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1136\/bjsports-2016-096291","volume":"50","author":"JS Thornton","year":"2016","unstructured":"Thornton, J. S. et al. Physical activity prescription: a critical opportunity to address a modifiable risk factor for the prevention and management of chronic disease: a position statement by the Canadian Academy of Sport and Exercise Medicine: Table 1. Br. J. Sports Med. 50, 1109\u20131114 (2016).","journal-title":"Br. J. Sports Med."},{"key":"1437_CR51","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1093\/ajcn\/86.5.1486","volume":"86","author":"X Gao","year":"2007","unstructured":"Gao, X. et al. Prospective study of dietary pattern and risk of Parkinson disease. Am. J. Clin. Nutr. 86, 1486\u20131494 (2007).","journal-title":"Am. J. Clin. Nutr."},{"key":"1437_CR52","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3233\/JPD-230257","volume":"14","author":"CM Kopil","year":"2024","unstructured":"Kopil, C. M. et al. A Coalition to Advance Treatments for Parkinson\u2019s Disease, Dementia with Lewy Bodies, and Related Disorders. J. Parkinsons Dis. 14, 1105\u20131114 (2024).","journal-title":"J. Parkinsons Dis."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01437-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01437-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01437-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:02:47Z","timestamp":1791266567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01437-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1437"],"URL":"https:\/\/doi.org\/10.1038\/s41531-026-01437-1","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.A. is a Scientific advisor to Signant Health & NovoNordisk. B.dM. is a Guest Editor for a Special Collection in npj Parkinson\u2019s disease on \u201cEnvironmental risk factors for Parkinson\u2019s disease\u201d; she was not involved in the journal\u2019s review of, nor decisions related to, this manuscript. B.dM. reports grant funding from NIEHS, APDA, US DoD, and Parkinson\u2019s Foundation; consulting fees from The Miller Firm and Bell Legal Group; payment for expert testimony from the US DoJ related to Camp Lejeune litigation; support for attending meetings from Parkinson\u2019s Foundation, The Michael J. Fox Foundation for Parkinson\u2019s Research, the University of Georgia, the World Federation of Neurology; participation in a DSMB or SAB for the APDA and MJFF. ERD reports honoraria from Adivo Associates France, American Neurological Association, Dartmouth, Elsevier, HMP Education, International Parkinson and Movement Disorder Society, Massachusetts Medical Society, Michael J. Fox Foundation, National Institutes of Health, National Multiple Sclerosis Society, Northwestern University, Patient-Centered Outcomes Research Institute, Philadelphia Neurological Society, Stanford University, Stony Brook, Sutter Health, Texas Neurological Society, University of Toronto; consulting fees from Abbott, Abbvie, Acadia, Acorda Therapeutics, Advarra, Aspen Neuroscience, Inc., Bial Pharmaceuticals, Biogen, Biohaven Pharmaceuticals, BioSensics, Boehringer Ingelheim, Caraway Therapeutics, Cerevance, CuraSen, DConsult2, Denali Therapeutics, Eli Lilly, Genentech, HanAll BioPharma, Health & Wellness Partners, HMP Education, Kairos Cinema, LLC (PBS), Karger, KOL groups, Life Sciences Consultant, Mediflix, Medrhythms, Merck, Mitsubishi Tanabe Pharma America, Inc., MJH Holdings, NACCME, Novartis, Otsuka, Praxis Medicine, Remepy, Sanofi, Seelos Therapeutics, Spark Therapeutics, Springer Healthcare, Synucure Therapeutics, Theravance Biopharmaceuticals, Vima Therapeutics, VivoSense, WebMD; grants from Averitas Pharma, Biogen, Burroughs Wellcome Fund, Michael J. Fox Foundation, National Institutes of Health, Pfizer, Photopharmics, Roche, Safra Foundation; ownership interests in Included Health, Mediflix, SemCap, Synapticure; patents with the Chorea Index. S.M.G. reports grant support from Michael J. Fox Foundation, US National Institutes of Health, US Department of Defense, US Veterans Administration; consulting fees from Michael J. Fox Foundation and Alkahest. P.G.-L. reports grant support from the Parkinson\u2019s Foundation and the Michael J. Fox Foundation. CMT declares consultancies for Praxis (advisory board via the International Parkinson\u2019s and Movement Disorder Society), Jazz\/Cavion, and Roche Genentech. She declares data monitoring committee service for Bial and Hillhurst. C.M.T. also declares grant support to her institution from The Michael J. Fox Foundation, National Institutes of Health, Gateway LLC, Department of Defense, Roche Genentech, and Parkinson Foundation. A.T. is an employee of the Environmental Working Group, a nonprofit research and advocacy organization. A.T. declares no personal financial conflict of interest. Within the scope of their employment, A.T. has prepared written and oral comments on behalf of EWG to the U.S. Environmental Protection Agency, as well as state and local agencies regarding regulation of pesticides as well as drinking water quality. As an organization, EWG evaluates and publicly comments on health impacts of drinking water contaminants in a publicly viewable database of drinking water contaminants (\n                      \n                      ). EWG also licenses, for a fee, the data in this database to other organizations, including water filter companies, in furtherance of our work. A.W.W. receives funding from the the National Instituties of Health. J.B., N.L., A.L.F., S.M., K.W., and C.W. are employees of the Parkinson\u2019s Foundation. The remaining authors report no relevant disclosures related to the current manuscript.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"241"}}